UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028695
Receipt number R000032846
Scientific Title Oral L-citrulline and Transresveratrol supplementation study for erectile function in men with phosphodieserase 5 inhibitors: randomized, double-blind, placebo-controlled crossover pilot study.
Date of disclosure of the study information 2017/08/18
Last modified on 2019/03/13 21:37:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Oral L-citrulline and Transresveratrol supplementation study for erectile function in men with phosphodieserase 5 inhibitors: randomized, double-blind, placebo-controlled crossover pilot study.

Acronym

L-citrulline and Transresveratrol supplementation study for erectile function.

Scientific Title

Oral L-citrulline and Transresveratrol supplementation study for erectile function in men with phosphodieserase 5 inhibitors: randomized, double-blind, placebo-controlled crossover pilot study.

Scientific Title:Acronym

L-citrulline and Transresveratrol supplementation study for erectile function.

Region

Japan


Condition

Condition

Erectile Dysfunction

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Improving erectile function

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Sexual Health Inventory for Men

Key secondary outcomes

Erection Hardness Score
Aging Male Scale (Sexual Domain)


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Oral L-citrulline and Transresveratrol 4-week supplementation

Interventions/Control_2

Oral placebo 4-week

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Score below 16 of Sexual Health Inventory for Men, despite on-demand use of PDE5i

Key exclusion criteria

Contraindication for PDE5i
Without nerve sparing, radical prostatectomy

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Masato
Middle name
Last name Shirai

Organization

Juntendo University Urayasu Hospital

Division name

Department of Urology

Zip code

2790021

Address

2-1-1, Tomioka, Urayasu City, Chiba, Japan

TEL

+81-47-353-3111

Email

masatos@juntendo-urayasu.jp


Public contact

Name of contact person

1st name Masato
Middle name
Last name Shirai

Organization

Juntendo University Urayasu Hospital

Division name

Department of Urology

Zip code

2790021

Address

2-1-1, Tomioka, Urayasu City, Chiba, Japan

TEL

+81-47-353-3111

Homepage URL


Email

masatos@juntendo-urayasu.jp


Sponsor or person

Institute

Juntendo University Urayasu Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Men's health clinic, Tokyo
Oosaka University
Iwasa clinic
Kageyama clinic

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization

Institutional Review Board, Juntendo University Urayasu Hospital

Address

2-1-1, Tomioka, Urayasu City, Chiba, Japan

Tel

+81-47-353-3111

Email

rinri-urayasu@juntendo-urayasu.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学浦安病院(千葉県)Juntendo University Urayasu Hospital
メンズヘルスクリニック東京(東京都)Men’s health clinic, Tokyo
大阪大学(大阪府) Oosaka University
岩佐クリニック (大阪府)Iwasa clinic
かげやま医院  (静岡県)Kageyama clinic


Other administrative information

Date of disclosure of the study information

2017 Year 08 Month 18 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

20

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 03 Month 10 Day

Date of IRB

2015 Year 04 Month 09 Day

Anticipated trial start date

2015 Year 04 Month 09 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry

2018 Year 04 Month 30 Day

Date trial data considered complete

2018 Year 04 Month 30 Day

Date analysis concluded

2018 Year 04 Month 30 Day


Other

Other related information



Management information

Registered date

2017 Year 08 Month 16 Day

Last modified on

2019 Year 03 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032846


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name